Praxis Precision Medicines, Inc. (PRAX) Stock Analysis
A live, multi-source view of Praxis Precision Medicines, Inc. (PRAX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE.
Sector: Healthcare · Industry: Biotechnology · United States · 168 employees · praxismedicines.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Praxis Precision Medicines, Inc. (PRAX) had a market capitalization of $9.82B (forward -37.9) and a beta of 2.78; the shares traded in a 52-week range of $37.19 – $392.70 (771.5% over the year).
- Market cap
- $9.82B
- Enterprise value
- $9.07B
- Forward P/E
- -37.9
- Price / book
- 7.32
- EPS (trailing)
- $-12.97
- EPS (forward)
- $-9.29
- Payout ratio
- 0.0%
- 52-week range
- $37.19 – $392.70
- 52-week change
- 771.5%
- Beta
- 2.78
- Average volume
- 461,835
- Shares outstanding
- 27.9M
- Short % of float
- 13.34%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Praxis Precision Medicines, Inc. (PRAX) last closed at $338.57 (the last completed close before that scan).
Technicals at the scan: RSI 44 (neutral territory), price -6.5% versus its 20-day average, 20-day versus 50-day average spread +6.6%, MACD histogram -4.47.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 75/100.
Next scheduled company event: in 59 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 1 buy and 0 sells of PRAX; corporate insiders filed 0 buys and 0 sells (1 filer, latest disclosure 2026-09-04). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Gilbert Ray Cisneros, Jr. (1B/0S). Who is trading what
RapidTradeView pick record
PRAX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Praxis Precision Medicines, Inc. (PRAX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell PRAX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.